MetLife
MET
$92.54
-0.78%
MetLife is one of the largest life insurers in the US by assets, providing a broad range of life insurance, annuity, and employee benefit products across six segments: Group Benefits, Retirement and Income Solutions, Asia, Latin America, EMEA, and MetLife Holdings. As a global insurance giant with a market cap exceeding $59 billion, it holds leading positions in the US, Japan, Mexico, and Chile, distinguishing itself through scale and geographic diversification. The current investor narrative centers on MetLife's ability to sustain margin expansion and earnings growth amid a rising interest rate environment, which benefits its spread-based businesses, while also navigating regulatory shifts and competitive pressures in its core markets. Recent financial trends show steady revenue growth and improving profitability, driving renewed interest in the stock.…
MET
MetLife
$92.54
MET 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on MetLife's 12-month outlook, with a consensus price target around $96.63 and implied upside of +4.4% versus the current price.
Average Target
$96.63
0 analysts
Implied Upside
+4.4%
vs. current price
Analyst Count
—
covering this stock
Price Range
$75 - $106
Analyst target range
MetLife is covered by 16 analysts, with a consensus recommendation of 'Buy' (mean score 1.94 on a 1-5 scale, where 1 is Strong Buy). The average target price is $96.00, implying a modest 2.1% upside from the current price of $94.00. The distribution shows 8 Buy/Overweight ratings, 5 Hold/Neutral, and 3 Sell/Underweight, indicating a generally bullish but cautious consensus. The target range spans from a low of $75.00 (20.2% downside) to a high of $105.00 (11.7% upside). The wide spread reflects uncertainty around interest rate sensitivity and competitive dynamics. The high target of $105 assumes continued margin expansion and favorable macro conditions, while the low target of $75 prices in potential earnings headwinds from lower rates or adverse claims. Recent ratings from major firms (Keefe Bruyette, Evercore, Jefferies, Wells Fargo, Mizuho, UBS, Barclays, Morgan Stanley) are predominantly positive, with no downgrades in the past month, signaling strong institutional conviction. The tight clustering of recent 'Overweight' and 'Buy' ratings suggests analysts see limited downside risk at current levels.
Bulls vs Bears: MET Investment Factors
MetLife presents a mixed picture: strong earnings growth, expanding margins, and a compelling valuation discount are offset by limited near-term upside potential and recent price strength. The bull case rests on sustained margin expansion and favorable interest rates, while the bear case highlights currency risks and modest revenue growth. Currently, the evidence slightly favors the bull side due to the deep valuation discount and robust free cash flow, but the stock's proximity to its 52-week high and modest analyst upside suggest limited near-term gains. The key tension is whether earnings growth can accelerate enough to justify the forward PE compression, or if macro headwinds will stall momentum.
Bullish
- Strong Earnings Growth Trajectory: Q1 2026 net income rose to $1.19 billion from $0.95 billion a year ago, a 25% increase. EPS improved to $1.75 from $1.29, demonstrating robust earnings momentum.
- Attractive Valuation Discount: Forward PE of 8.5x is a 61% discount to the industry average of 22x, and trailing PE of 16.4x is below the five-year average. This suggests the stock is undervalued relative to peers and history.
- Expanding Margins and Profitability: Gross margin improved to 37.2% in Q1 2026 from 25.9% a year earlier, and operating margin rose to 7.9% from 7.4%. ROE of 11.9% exceeds the industry average, reflecting efficient capital use.
- Strong Free Cash Flow Generation: TTM free cash flow of $16.53 billion provides ample capacity for dividends (3.2% yield) and share buybacks. The payout ratio of 50.4% is sustainable, supporting shareholder returns.
Bearish
- Limited Upside to Analyst Targets: The average analyst target of $96 implies only 2.1% upside from the current price of $94. The high target of $105 offers 11.7% upside, but the low target of $75 suggests 20.2% downside risk.
- Near 52-Week High, Overextended: The stock trades at 99.1% of its 52-week high of $94.84, with a 1-month gain of 9.5% versus the S&P 500's 0.3%. This rapid run-up increases the risk of a pullback.
- Currency Headwinds in Asia: The Asia segment contributes 25% of earnings, primarily from Japan. Yen depreciation and other currency fluctuations can compress reported earnings, as seen in prior quarters.
- Modest Revenue Growth Rate: Q1 2026 revenue grew only 4.4% YoY to $19.07 billion. While steady, this growth rate is below the double-digit expansion seen in some financial peers, limiting earnings acceleration.
MET Technical Analysis
MetLife is in a sustained uptrend, with the stock price up 21.6% over the past year, significantly outperforming the S&P 500's 18.4% gain. The current price of $94.00 sits at 99.1% of its 52-week range ($67.33–$94.84), indicating strong momentum and near-term overextension, but also reflecting bullish sentiment. The stock is trading just 0.9% below its 52-week high of $94.84, suggesting it is testing resistance levels. Short-term momentum is accelerating sharply, with a 1-month gain of 9.5% and a 3-month gain of 20.4%, both far exceeding the S&P 500's 0.3% and 4.7% returns over the same periods. This divergence—where short-term strength outpaces the longer-term trend—signals a powerful bullish phase, potentially driven by positive earnings catalysts or sector rotation into insurance stocks. The stock's beta of 0.78 indicates it is 22% less volatile than the market, making it a relatively defensive holding. Key support lies at the 52-week low of $67.33, while resistance is at the 52-week high of $94.84. A breakout above $94.84 would confirm the uptrend and open the door to further gains, while a pullback from these levels could see support near the 50-day moving average (around $85). The low beta suggests that any downside may be less severe than the broader market.
Beta
0.78
0.78x market volatility
Max Drawdown
-18.3%
Largest decline past year
52-Week Range
$67-$95
Price range past year
Annual Return
+18.0%
Cumulative gain past year
| Period | MET Return | S&P 500 |
|---|---|---|
| 1m | +5.1% | +0.6% |
| 3m | +19.1% | +3.4% |
| 6m | +22.1% | +7.1% |
| 1y | +18.0% | +16.4% |
| ytd | +15.2% | +8.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
MET Fundamental Analysis
MetLife's revenue trajectory is steadily growing, with Q1 2026 revenue of $19.07 billion, up 4.4% year-over-year from $18.26 billion in Q1 2025. The multi-quarter trend shows consistent expansion: Q4 2025 revenue was $23.81 billion (seasonally higher), Q3 2025 was $16.88 billion, and Q2 2025 was $17.18 billion. Growth is driven by the US Group Benefits and Retirement segments, which together contributed about 48% of 2024 adjusted earnings, while Asia (led by Japan) added 25%. The company's diversified revenue base provides stability, though the Asia segment faces currency headwinds. Profitability is solid, with net income of $1.19 billion in Q1 2026, up from $0.95 billion in Q1 2025, and gross margin improving to 37.2% from 25.9% a year earlier. Operating margin expanded to 7.9% in Q1 2026 from 7.4% in Q1 2025, reflecting better cost control and favorable underwriting. The net margin of 6.2% is healthy for a life insurer, though it remains below the industry's top quartile. MetLife's balance sheet is robust, with a debt-to-equity ratio of 0.71 and a current ratio of 0.65, indicating adequate liquidity. Free cash flow (TTM) is $16.53 billion, providing ample capacity for dividends and share buybacks. ROE stands at 11.9%, above the industry average, signaling efficient capital use. The company's strong cash generation supports a dividend yield of 3.2% and a payout ratio of 50.4%.
Quarterly Revenue
$19.1B
2026-03
Revenue YoY Growth
+4.4%
YoY Comparison
Gross Margin
37.2%
Latest Quarter
Free Cash Flow
$16.5B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is MET Overvalued?
Since MetLife has positive net income, the PE ratio is the primary valuation metric. The trailing PE is 16.4x, while the forward PE is 8.5x, a significant discount that implies the market expects strong earnings growth ahead—likely driven by higher interest rates and operational efficiencies. The gap between trailing and forward PE suggests a favorable earnings outlook. Compared to the industry average PE of 22x (based on sector data), MetLife's trailing PE of 16.4x represents a 25% discount, and its forward PE of 8.5x is even more attractive. This discount is justified by the company's lower growth profile relative to tech-driven insurers, but its strong free cash flow and dividend yield add value. Historically, MetLife's trailing PE has ranged from 3.9x (mid-2021) to 795.9x (early 2023, due to depressed earnings). The current 16.4x is near the lower end of its five-year range, suggesting the stock is undervalued relative to its own history. The PB ratio of 1.85x is also below the historical average of ~1.9x, reinforcing the value case.
PE
16.4x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 4x~21x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
7.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: MetLife's debt-to-equity ratio of 0.71 is manageable, but the current ratio of 0.65 indicates potential liquidity constraints in stress scenarios. Net margin of 6.2% is healthy but below top-quartile insurers, and revenue growth of 4.4% YoY is modest. The company's reliance on spread income makes it sensitive to interest rate changes; a 100bp rate cut could reduce net income by an estimated 5-10%. Additionally, the Asia segment's 25% earnings contribution exposes MetLife to currency volatility, particularly the yen, which has weakened over the past year.
Market & Competitive Risks: The stock's beta of 0.78 suggests lower market correlation, but its trailing PE of 16.4x, while below the industry average of 22x, could compress further if earnings disappoint. Competitive pressures from fintech insurers and traditional peers like Prudential may erode market share. Regulatory changes, such as tighter capital requirements under Solvency II or US state insurance regulations, could increase compliance costs. The stock's 1-month gain of 9.5% versus the S&P 500's 0.3% indicates potential overextension, raising the risk of a mean-reversion pullback.
Worst-Case Scenario: A combination of Fed rate cuts, yen depreciation, and adverse claims experience could drive earnings below expectations. In this scenario, the stock could fall to the analyst low target of $75, representing a 20.2% decline from the current price of $94. The 52-week low of $67.33 implies a potential 28.4% downside. Historically, the stock's max drawdown is -18.33%, but a severe macro shock could exceed that. An investor could lose up to 28% if the stock revisits its 52-week low.